RxDoctor Payments DataLook up a doctor →

Geoffrey Kostiner, MD

Urology · Newport News, VANPI 1235123530

Payments from drug & device makers

$24,865in general payments, 2019–2025

Across 506 payments — averaging $49.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$5K
  • Sanofi US Services Inc.$4K
  • Procept Biorobotics Corporation$3K
  • Axonics, Inc.$2K
  • Medtronic$1K
  • AbbVie$1K
  • plus $8K from 54 others

What the payments were for

  • Consulting fees$9274%
  • Speaking & faculty fees$3,35013%
  • Travel & lodging$8,38734%
  • Food & beverage$12,20149%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teleflex LLC27$4,825
Sanofi US Services Inc.5$4,062
Procept Biorobotics Corporation27$2,849
Axonics, Inc.30$2,405
Medtronic(2 entities)43$1,232
AbbVie(2 entities)50$1,019
Telix Pharmaceuticals5$848
Sumitomo Pharma America, Inc.21$525
Pfizer28$497
Neotract Inc.8$457
Bayer21$414
BD1$393
Johnson & Johnson(2 entities)20$389
Astellas Pharma US Inc20$387
Boston Scientific15$347
Urogen Pharma, Inc.18$343
Dornier Medtech America, Inc1$341
Dendreon Pharmaceuticals LLC10$329
Endo Pharmaceuticals Inc.22$326
KARL Storz Endoscopy-america4$259
Accord Healthcare, Inc.6$258
Myriad Genetic Laboratories, Inc.17$251
Merck10$222
Antares Pharma, Inc.11$184
Olympus America Inc.6$139
Progenics Pharmaceuticals, Inc.7$138
Blue Earth Diagnostics5$110
Amgen7$106
Endo USA, Inc.5$99
Koelis Inc.3$87
Immunitybio, Inc.4$70
Novartis3$70
Coloplast3$65
Mission Pharmacal Company3$64
Laborie Medical Technologies Corp.3$64
Clarus Therapeutics Inc.4$60
Halozyme Inc3$55
ABC Home Medical Supply, Inc.2$52
C. R. Bard, Inc. & Subsidiaries2$44
Urovant Sciences Inc2$43
Tolmar Pharmaceuticals, Inc.2$37
Inspire Medical Systems, Inc.1$37
Valencia Technologies Corporation2$35
Myovant Sciences Inc.2$31
Bioprotect Medical, Inc.1$27
180 Medical, Inc.1$27
Novo Nordisk1$22
Bluewind Medical1$22
Innovation Technologies Inc1$21
Azurity Pharmaceuticals, Inc.1$20
Tempus AI, Inc1$19
Ambu Inc.1$19
Dentsply IH Inc.1$18
Cook Medical LLC2$17
Photocure Inc1$16
AstraZeneca1$15
Rochester Medical Corporation1$15
Irhythm Technologies, Inc.1$14
Foundation Medicine, Inc.1$14
Profound Medical Corp.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,865 in reported general payments places this provider in the 85th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$447,912
Medicare patients
1,030
Services billed
9,649

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide31$551,166
MyrbetriqMirabegron63$73,305
OrgovyxRelugolix24$62,401
GemtesaVibegron51$44,747
Silodosin74$7,511
Tamsulosin Hcl391$6,109
Potassium Citrate ErPotassium Citrate19$5,727
Trospium Chloride32$3,562
Finasteride147$1,766
Methenamine Hippurate12$1,281
Testosterone Cypionate20$980
Alfuzosin Hcl ErAlfuzosin Hcl41$769
Cephalexin120$373
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen136$291
Terazosin Hcl16$219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$387$624,47094 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$525$107,14875 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 300 urology providers in Virginia.

Other urology in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →